# The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus

> **NCT01905202** · PHASE1 · UNKNOWN · sponsor: **Effexus Pharmaceutical** · enrollment: 13 (estimated)

## Conditions studied

- Barrett's Esophagus

## Interventions

- **DRUG:** Secretrol

## Key facts

- **NCT ID:** NCT01905202
- **Lead sponsor:** Effexus Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2015-04
- **Final completion:** —
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2014-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01905202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01905202, "The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01905202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*